February 8, 2020 / 8:14 PM / 10 days ago

BRIEF-Adverum Biotechnologies Reports New Interim Data From Cohorts 1 & 2 Of Optic Phase 1 Trial Of ADVM-022

Feb 8 (Reuters) - Adverum Biotechnologies Inc:

* ADVERUM BIOTECHNOLOGIES REPORTS NEW INTERIM DATA FROM COHORTS 1 AND 2 OF OPTIC PHASE 1 TRIAL OF ADVM-022 INTRAVITREAL GENE THERAPY FOR WET AMD AT ANGIOGENESIS, EXUDATION, AND DEGENERATION 2020

* ADVM-022 DEMONSTRATED A ROBUST EFFICACY SIGNAL AND EVIDENCE OF A DOSE RESPONSE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below